Sucampo Pharmaceuticals (SCMP) Given a $23.00 Price Target by Maxim Group Analysts
“Sucampo’s stock has risen sharply in the past few weeks (from ~$10 to $16+) on no new fundamental news. However, a Bloomberg story has been circulating that the company may be entertaining suitors. We have no specific knowledge to confirm this, but do see an undervalued company that is generating free cash flow and has a strong (orphan) pipeline. Our last note (from 11/21) reviewed the R&D Day which focused on two key pipeline products, VTS-270 (Neeman Pick Disease) and CPP-1X/sulindac (Familial Adenomatous Polyposis ).”,” Maxim Group’s analyst commented.
Other equities research analysts have also issued reports about the company. Mizuho lowered Sucampo Pharmaceuticals from a buy rating to a neutral rating and lowered their price objective for the company from $14.00 to $12.00 in a research note on Tuesday, October 3rd. B. Riley upped their price objective on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the company a buy rating in a research note on Wednesday, December 6th. Leerink Swann began coverage on Sucampo Pharmaceuticals in a research note on Monday, August 21st. They issued an outperform rating and a $15.00 price objective on the stock. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, October 3rd. Finally, BidaskClub upgraded Sucampo Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, December 5th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Sucampo Pharmaceuticals presently has an average rating of Buy and a consensus target price of $16.60.
Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) opened at $16.00 on Thursday. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.70. The firm has a market capitalization of $746.19, a P/E ratio of 10.96, a PEG ratio of 4.76 and a beta of 1.47. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The company had revenue of $61.27 million for the quarter, compared to analyst estimates of $58.05 million. During the same period in the prior year, the company posted $0.30 EPS. The company’s revenue was up 5.9% compared to the same quarter last year. sell-side analysts predict that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SCMP. Vanguard Group Inc. grew its position in Sucampo Pharmaceuticals by 48.9% during the 1st quarter. Vanguard Group Inc. now owns 1,456,787 shares of the biopharmaceutical company’s stock worth $16,024,000 after acquiring an additional 478,226 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in Sucampo Pharmaceuticals by 2.3% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 180,303 shares of the biopharmaceutical company’s stock worth $1,984,000 after acquiring an additional 4,104 shares during the last quarter. Capstone Asset Management Co. grew its position in Sucampo Pharmaceuticals by 2.1% during the 2nd quarter. Capstone Asset Management Co. now owns 12,360 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 260 shares during the last quarter. Louisiana State Employees Retirement System grew its position in Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 100 shares during the last quarter. Finally, Strs Ohio grew its position in Sucampo Pharmaceuticals by 34.4% during the 2nd quarter. Strs Ohio now owns 60,900 shares of the biopharmaceutical company’s stock worth $639,000 after acquiring an additional 15,600 shares during the last quarter. Institutional investors and hedge funds own 65.31% of the company’s stock.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.